At Nexus BioQuest, our scientists are experts in NK cell biology and offer a comprehensive suite of assays to test novel therapeutics. View our case study to see how NK cell driven ADCC is being developed for oncology and autoimmunity; targeting either unwanted tumour cells or autoreactive immune cells.
We recently started a new scientific initiative with the super catchy name of “speed science” which does what it says on the tin- our scientists get 10 minutes to present an immunology topic of their choice, this can be a project they are working on, a paper or a technology. This was inspired by the 3-minute thesis concept. We’ve found speed science provides a good work out for the brain as the presenter needs to be clear, concise and focused with their messaging. Our aim with this initiative is to challenge and improve our science communication skills, to inspire curiosity and to increase the diversity of immunology knowledge within the team; working towards our company values of curiosity and drive. We look forward to sharing some of the topics the team have enjoyed discussing over the coming weeks and in the meantime we challenge you to give it a go and test your science communication skills! Rhiannon Jenkinson, CSO
How did you celebrate International Day of Immunology? At Nexus BioQuest we celebrated our favorite immune cell. It has been fun to hear from our collaborators what their favorite immune cell is and why?
Macrophages are highly plastic and can differentiate into a range of activated phenotypes driven by external signals under various disease conditions. Therapeutic driven modulation of macrophage phenotype has the potential to modulate many different disease types where macrophage play a key role in either driving or regulating disease. We present here a range of macrophage polarisation conditions that model macrophage phenotypes found in different disease states run in 96 well or 384 well screening mode.
Tool for screening immune therapeutics; bench mark therapeutics in an immune check point inhibitor (Pembrolizumab) sensitive assay or ADCC
Dr Rhiannon Jenkinson (CSO) and Jody Sawyer (VP of Business Development) showcased our services spanning preclinical screening, efficacy, translational models, predictive immunotoxicology and clinical Biomarkers, within the IO, Autoimmunity and Inflammatory space. Connecting with our current clients and meeting new ones. We will be back in 2024, continuing to support companies within the west coast Biotech hubs. Watch our Events page to see when we are visiting or Contact Us in the meantime to see how we can help.
Dr Rhiannon Jenkinson (CSO) and Jody Sawyer (VP of Business Development) had a fantastic time at the IO conference in Boston, meeting with current clients and new companies. After spending time at the conference, visiting the Boston Biotech hub and dining with clients the Nexus BioQuest team were extremely grateful for the fruitful discussions and excited about future collaborations. The Nexus Team will be back in Boston in early 2024 to visit clients and later in the year for the Special AACR conference, see more on our Events page. If you are interested in meeting the team in March 2024 Contact Us
Accelerate the buying process by finding Nexus BioQuest as a supplier on Science Exchange Science Exchange | Supplier Orchestration | R&D Marketplace and Scientist.com World’s Leading AI-Powered R&D Marketplace | Scientist.com